尾加压素Ⅱ与糖尿病  

Urotensin Ⅱ and diabetes

作　　者：王红霞[1] 张立克[1] 唐朝枢[2] 

机构地区：[1]首都医科大学病理生理学教研室,北京100069 [2]北京大学第一医院心血管研究所,北京100034

出　　处：《国际病理科学与临床杂志》2008年第2期147-152,共6页Journal of International Pathology and Clinical Medicine

基　　金：国家"973"重大基础研究发展规划项目(2006CB503807);首都医科大学校自然基金(2007ZR07)~~

摘　　要：尾加压素Ⅱ(urotensin Ⅱ,UⅡ)最早是从鱼尾部下垂体中分离出的调节肽,近来已从人体中克隆出来,并发现体内一种孤立的G蛋白偶联受体GPR14是其特异性受体。UⅡ与GPR14结合后,参与许多生物学效应,如调节内分泌,调节渗透压平衡,调节胃肠道平滑肌及心血管收缩功能等,是迄今体内最强的缩血管活性肽。UⅡ不仅与许多人类心血管疾病如高血压,充血性心力衰竭(CHF),冠心病和动脉粥样硬化有关,而且研究发现,糖尿病患者血液中UⅡ含量升高。初步研究表明,UⅡ的基因多态性和2型糖尿病的发生有关;尾加压素Ⅱ还可抑制胰岛素的释放。Urotensin Ⅱ （UⅡ） is a regulatory peptide which was initially isolated from the goby urophysis, and now has been cloned in human. It has also been found that orphan G protein-coupled re- ceptor GPR14 is its specific receptor. Through stimulating GPR14, UⅡ involves many biological effects, such as mediating endocrine effect, mediating osmotic pressure balance, mediating contractile function of gastrointestinal tract and cardiovascular smooth muscle. It has been suggested that UII may have a role in the pathophysiology of a number of human diseases such as hype.rtension, congestive cardiac failure, coronary artery disease and artherosclerosis. Initial studies showed that certain polymorphisms in the UⅡ gene were been associated with the development of type 2 diabetes; In perfused rat pancreas models, UII has inhibited insulin release in response to glucose; UⅡ has also been shown to be elevated in patients with type 2 diabetes.

关 键 词：尾加压素Ⅱ 生物学效应 糖尿病 

分 类 号：R587.1[医药卫生—内分泌]